Connected profiles12
Exact peptide identities attached to retained registry observations carrying this condition label.
Coverage-gated living condition brief
Obesity peptide evidence brief
A cited Obesity peptide evidence brief across 36 exact-label ClinicalTrials.gov records, 12 connected profiles, and 10 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
Registry records
36 selected records.
Connected peptides
12 profiles.
Registry update years
2013–2026 in selected records.
Direct collection answer · published August 17, 2026
What peptide evidence does PeptideScanner carry for Obesity?
PeptideScanner’s selected collection contains 36 retained ClinicalTrials.gov records carrying the exact condition label “Obesity,” connected to 12 peptide profiles across 10 registry-update years.
That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Obesity, and it is not a safety or efficacy assessment.
Indication intelligence
Selected evidence landscape
Trial phases6
Phase labels copied from the retained ClinicalTrials.gov versions.
Phase 3 (15)Phase 2 (9)Phase 1 (5)Phase 4 (4)Not applicable (2)Early Phase 1 (1)
Registry statuses5
Overall statuses at each retained observation, not necessarily current today.
Completed (18)Recruiting (7)Active, not recruiting (6)Not yet recruiting (3)Enrolling by invitation (2)
Across the connected peptide profiles, PeptideScanner also carries 571 selected PubMed records and 55 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Obesity unless their own cited source says so.
Related profile context
Literature connected through these peptide profiles
This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Obesity.
Semaglutide · source record 2026-08-15
Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.
PubMed lists PMID 42602345 in Canadian journal of kidney health and disease as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Liraglutide · source record 2026-08-14
Treatment of obesity with liraglutide in bipolar disorder: a case report.
PubMed lists PMID 42597211 in Frontiers in psychiatry as Case Reports, Journal Article, with publication-date metadata of 2026-07-30 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Tirzepatide · source record 2026-08-14
Inflammation-mediated facial nodules to compounded tirzepatide.
PubMed lists PMID 42598502 in JAAD case reports as Letter, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Maridebart cafraglutide · source record 2026-08-13
Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.
PubMed lists PMID 42592044 in Antibody therapeutics as Journal Article, Review, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug maridebart-cafraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Retatrutide · source record 2025-09-02
Retatrutide.
PubMed lists PMID 39429457 in Clinical diabetes : a publication of the American Diabetes Association as Journal Article, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Setmelanotide · source record 2026-01-27
Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist.
PubMed lists PMID 27339818 in British journal of pharmacology as Journal Article, with publication-date metadata of 2016-07-27 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Open attributed literature record →Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
Record added
ClinicalTrials.gov record NCT02817659
PeptideScanner retained ClinicalTrials.gov record NCT02817659 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-30, and PeptideScanner's reviewed identity mapping was glucagon.
- PeptideScanner change date
- August 14, 2026
- Cited source date
- March 30, 2026
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT05093634
PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was setmelanotide.
- PeptideScanner change date
- August 14, 2026
- Cited source date
- August 6, 2026
- Evidence lane
- Clinical trials
Record added
ClinicalTrials.gov record NCT05882045
PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.
- PeptideScanner change date
- August 14, 2026
- Cited source date
- July 30, 2026
- Evidence lane
- Clinical trials
Exact-record source chronology
Obesity registry timeline
Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.
2026
25 recordsTirzepatide · 2026-08-12
ClinicalTrials.gov record NCT07463846
Recruiting at the retained observation.
Open cited registry record →Survodutide · 2026-08-11
ClinicalTrials.gov record NCT06077864
Completed at the retained observation.
Open cited registry record →Tirzepatide · 2026-08-11
ClinicalTrials.gov record NCT06965413
Active, not recruiting at the retained observation.
Open cited registry record →Setmelanotide · 2026-08-06
ClinicalTrials.gov record NCT05093634
Completed at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-08-04
ClinicalTrials.gov record NCT07684235
Recruiting at the retained observation.
Open cited registry record →Cagrilintide · 2026-08-04
ClinicalTrials.gov record NCT07745504
Not yet recruiting at the retained observation.
Open cited registry record →Cagrilintide · 2026-08-03
ClinicalTrials.gov record NCT07220759
Active, not recruiting at the retained observation.
Open cited registry record →Retatrutide · 2026-07-30
ClinicalTrials.gov record NCT05882045
Completed at the retained observation.
Open cited registry record →Retatrutide · 2026-07-30
ClinicalTrials.gov record NCT05929079
Completed at the retained observation.
Open cited registry record →Semaglutide · 2026-07-28
ClinicalTrials.gov record NCT07732426
Recruiting at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-07-24
ClinicalTrials.gov record NCT07037433
Recruiting at the retained observation.
Open cited registry record →Setmelanotide · 2026-07-23
ClinicalTrials.gov record NCT07496463
Enrolling by invitation at the retained observation.
Open cited registry record →Semaglutide · 2026-07-21
ClinicalTrials.gov record NCT06299098
Active, not recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-07-16
ClinicalTrials.gov record NCT06814938
Active, not recruiting at the retained observation.
Open cited registry record →Tirzepatide · 2026-07-15
ClinicalTrials.gov record NCT06934642
Recruiting at the retained observation.
Open cited registry record →Liraglutide · 2026-07-09
ClinicalTrials.gov record NCT04775082
Active, not recruiting at the retained observation.
Open cited registry record →Tirzepatide · 2026-07-09
ClinicalTrials.gov record NCT07693608
Not yet recruiting at the retained observation.
Open cited registry record →Semaglutide · 2026-07-08
ClinicalTrials.gov record NCT05616013
Completed at the retained observation.
Open cited registry record →Tirzepatide · 2026-07-07
ClinicalTrials.gov record NCT06893211
Completed at the retained observation.
Open cited registry record →Semaglutide · 2026-07-02
ClinicalTrials.gov record NCT05371496
Enrolling by invitation at the retained observation.
Open cited registry record →Maridebart cafraglutide · 2026-07-02
ClinicalTrials.gov record NCT07037459
Recruiting at the retained observation.
Open cited registry record →Mazdutide · 2026-05-27
ClinicalTrials.gov record NCT07469800
Recruiting at the retained observation.
Open cited registry record →Mazdutide · 2026-04-21
ClinicalTrials.gov record NCT06124807
Completed at the retained observation.
Open cited registry record →Glucagon · 2026-03-30
ClinicalTrials.gov record NCT02817659
Active, not recruiting at the retained observation.
Open cited registry record →Petrelintide · 2026-03-23
ClinicalTrials.gov record NCT06662539
Completed at the retained observation.
Open cited registry record →2025
1 recordSemaglutide · 2025-01-08
ClinicalTrials.gov record NCT06764056
Not yet recruiting at the retained observation.
Open cited registry record →2024
1 recordSemaglutide · 2024-08-30
ClinicalTrials.gov record NCT03574597
Completed at the retained observation.
Open cited registry record →2023
2 recordsLiraglutide · 2023-07-18
ClinicalTrials.gov record NCT03374956
Completed at the retained observation.
Open cited registry record →Liraglutide · 2023-01-20
ClinicalTrials.gov record NCT02967757
Completed at the retained observation.
Open cited registry record →2022
1 recordSemaglutide · 2022-01-19
ClinicalTrials.gov record NCT03548987
Completed at the retained observation.
Open cited registry record →2021
1 recordSemaglutide · 2021-11-11
ClinicalTrials.gov record NCT03611582
Completed at the retained observation.
Open cited registry record →2020
1 recordSemaglutide · 2020-12-24
ClinicalTrials.gov record NCT03842202
Completed at the retained observation.
Open cited registry record →2017
1 recordSemaglutide · 2017-12-02
ClinicalTrials.gov record NCT02079870
Completed at the retained observation.
Open cited registry record →2014
1 recordLeuprolide · 2014-05-14
ClinicalTrials.gov record NCT01160328
Completed at the retained observation.
Open cited registry record →2013
2 recordsLiraglutide · 2013-07-30
ClinicalTrials.gov record NCT01911468
Completed at the retained observation.
Open cited registry record →Liraglutide · 2013-07-15
ClinicalTrials.gov record NCT01899430
Completed at the retained observation.
Open cited registry record →- Condition matching is limited to exact labels on retained ClinicalTrials.gov v3 observations; PeptideScanner does not merge related diagnoses or synonyms.
- Coverage is selective and historical, not a complete or continuously current account of the registry or PubMed.
- The brief does not synthesize study outcomes, compare interventions, or make safety, efficacy, diagnosis, or treatment claims.